查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466293

重组蛋白市场：按产品、服务、最终用户、功能分类 - 全球预测 2024-2030

Recombinant Proteins Market by Product (Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins), Services (Cloning, Expression, Purification), End-User, Function - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年重组蛋白市场规模为50.5亿美元，预计2024年将达58亿美元，2030年将达130.4亿美元，复合年增长率为14.51%。

重组蛋白是透过将修饰的基因插入细菌、酵母或哺乳动物细胞等表现系统中来产生的，以产生具有高纯度和功能性的所需蛋白。 Recombinant Proteins 从事源自重组 DNA 技术的基因工程蛋白质的研究、开发、製造和商业化。由于感染疾病和慢性病的流行、新疗法和诊断方法的医疗支出增加以及生物製药公司研发投资的增加，对高品质重组蛋白的需求不断增加。基因组学技术的快速进步以及生技药品相对于小分子药物的日益采用正在推动重组蛋白的采用不断增加。然而，高昂的生产和维护成本可能会对最终用途产业使用重组 DNA 产生负面影响。此外，动物育种和饲料效率的新应用以及重组蛋白开发的大量投资预计将推动全球最终用途部门使用这些蛋白质。

主要市场统计
基准年[2023] 50.5亿美元
预测年份 [2024] 58亿美元
预测年份 [2030] 130.4亿美元
复合年增长率（%） 14.51%

黏附分子和受体在产品研究中的重要用途

黏附分子和受体对于细胞间通讯、迁移和免疫反应调节至关重要。这些被广泛用于了解癌症、发炎和感染疾病的研究。生长因子和趋化素控制细胞生长、分化和迁移过程。这些对于创伤治疗、组织修復和干细胞研究的应用至关重要。免疫反应蛋白是控制感染防御机制和发炎控制的免疫系统的重要组成部分。研究人员使用免疫反应蛋白来研究自体免疫疾病和疫苗开发。激酶蛋白在控制细胞分裂、生存、代谢和其他生物过程的细胞内讯号传导途径中至关重要。激酶蛋白作为癌症治疗和慢性发炎治疗的药物标靶具有重要的潜力。膜蛋白在细胞讯号传导、运输和黏附中很重要，并参与许多生理过程，这导致它们在药物发现和开发中的应用。重组代谢酶在调节细胞代谢和能量产生的生物途径中至关重要。这些用于针对糖尿病和肥胖症等代谢疾病的药物发现。调节蛋白控制基因表现和细胞过程，例如细胞凋亡和细胞週期进程。这些蛋白质广泛用于癌症治疗和其他涉及不受控制的细胞增殖和分化的疾病。结构蛋白为细胞和组织提供机械支撑，同时保持生物体内的结构完整性。它应用于组织工程和再生医学相关的生物医学研究。

服务 表达服务注重高产量和与目标蛋白质特性的兼容性。

重组蛋白的克隆涉及将目标基因插入适当的表达载体，产生指导宿主细胞中蛋白质生产的重组DNA分子。基于需求的克隆服务偏好包括高效率、特异性和对不同生物的适应性。表达是指将遗传讯息转化为功能性蛋白质产物的过程。有几个因素会影响表现系统的选择，包括生产力水平、与转译后修饰(PTM) 的兼容性以及下游应用所需的更高产量和纯度水平的放大难度。精製对于去除表达蛋白中的污染物以用于药物发现、诊断和研究等下游应用至关重要。对精製服务的需求包括高选择性、重现性、产量和最小的样品损失。随着分子生物学技术的进步使得同时创建多个克隆成为可能，对克隆服务的需求不断增加。表达服务透过宿主系统的改进而不断发展，以适应不同复杂程度的多种蛋白质。随着树脂化学和设备的进步，精製服务不断进步，从而实现更高的产量和产量。

最终用户：重组蛋白在製药和生物製药公司的广泛使用

学术研究机构是重组蛋白技术创新和高级研究的基础。这些实验室需要高品质、可靠且具成本效益的重组蛋白来进行结构生物学、功能研究、药物发现和诊断研究。受託製造厂商（CMO）和合约研发组织（CRO）为专门从事重组蛋白生产、分析开发和临床前测试的生物製药公司提供研发和产品开发外包服务。这些公司强调快速交付、有竞争力的价格和可客製化的服务，以满足客户的需求。生物製药公司需要高品质、符合 GMP 的重组蛋白来开发治疗和诊断方法。这些最终用户群体优先考虑品质、可靠性和经济高效的解决方案。此外，CRO 和 CMO 优先考虑满足截止日期和多样化客户的客製化产品，而製药和生物製药公司则需要严格的监管合规性和强大的製造能力。

功能：重组蛋白在药物发现和药物开发的潜在需求

重组蛋白对于诊断至关重要，有助于各种疾病的检测和监测。酵素结合免疫吸附检测法（ELISA）或侧流免疫检测是一种常见的诊断技术，利用重组蛋白作为抗原或抗体来检测与特定疾病相关的特定生物标记。重组蛋白在生技药品、疫苗、细胞和基因疗法的药物发现和製造中发挥重要作用，并作为潜在的治疗标靶和候选药物。此外，它还有助于进行高通量筛检测定，以识别针对特定疾病途径的先导化合物。诊断应用主要关注灵敏度、特异性、快速性和成本效益。相较之下，药物发现和开发强调重组蛋白的纯度、稳定性、扩充性和功能活性。

区域洞察

由于美洲拥有成熟的製药和生物技术公司，拥有先进的研究设施和确保高品质产品的法规，重组蛋白市场正在不断发展。此外，技术的进步、研发 (R&D) 资金的大幅增加、慢性病盛行率的上升以及对个人化药物的需求不断增长正在推动美洲对重组蛋白的需求。欧洲、中东和非洲地区是重组蛋白市场的新兴市场，因为对这些蛋白的使用有严格的规定，而且製造商必须遵守 GMP 标准。由于慢性病的流行、细胞生物学、生物化学、结构和生物物理研究活动的增加以及对高效生物製药的需求，亚太地区的重组蛋白市场正在不断增长。此外，生物製药公司和学术机构之间的技术进步和合作正在加速将实验室创新转化为商业性可行的产品，并且预计将促进世界各地最终用途部门对重组蛋白的采用。

FPNV定位矩阵

FPNV定位矩阵对于评估重组蛋白市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对重组蛋白市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，以获得市场竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1、重组蛋白市场规模及预测如何？

2.重组蛋白市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3. 重组蛋白市场的技术趋势和法规结构是什么？

4.重组蛋白市场主要厂商的市场占有率为何？

5. 进入重组蛋白市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 消费者越来越重视个人化医疗和蛋白质疗法
      • 老年人和儿童感染疾病和慢性病盛行率高
      • 生物製药和生物相似药蛋白的需求快速成长
    • 抑制因素
      • 重组蛋白成本与维护时间问题
    • 机会
      • 对生物标誌物发现的更多关注和对重组蛋白开发的投资激增
      • 重组蛋白在动物繁殖、饲料效率和健康方面的潜力不断增长
    • 任务
      • 替代产品的可用性和一些生产问题
  • 市场区隔分析
    • 产品：黏附分子和受体在研究中的重要用途
    • 服务：表达服务注重高产量和与目标蛋白质特性的兼容性
    • 最终用户：重组蛋白在製药和生物製药公司的广泛使用
    • 功能：重组蛋白在药物发现与开发的潜在需求
  • 市场趋势分析
    • 研究成本不断增加，整个美洲的医疗基础设施也不断增加。
    • 亚太地区慢性病盛行率和医学研究的重大投资
    • 扩大欧洲、中东和非洲地区药品生产设施和重组蛋白的监管指南。
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章重组蛋白市场：副产品

  • 黏附分子和受体
  • 生长因子和趋化素
  • 免疫反应蛋白
  • 激酶蛋白
  • 膜蛋白
  • 重组代谢酶
  • 调节蛋白
  • 结构蛋白

第七章重组蛋白市场：依服务分类

  • 复製
  • 表达
  • 精製

第 8 章重组蛋白市场：依最终用户分类

  • 学术研究所
  • 合约研究组织和合约製造组织
  • 製药和生物製药公司

第 9 章重组蛋白市场：按功能

  • 诊断
  • 药物发现与开发

第10章美洲重组蛋白市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太重组蛋白市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲重组蛋白市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • iTolerance 与 Northway Biotech 签署融合蛋白生产协议
    • Biovian 在芬兰製造工厂投资超过 5,000 万欧元
    • 富通生命科学公司收购 International Point of Care
    • Curia 利用 CHOZN 平台扩展细胞株开发服务
    • Future Fields 融资 1,120 万美元，扩大果蝇重组蛋白生产规模
    • 默克生物开发中心扩建，法国马蒂利亚克
    • Shenandoah Biotechnology 宣布扩大根据 cGMP 实践生产的 CTGrade 重组蛋白系列
    • FUJIFILM收购领先的重组蛋白製造商 Shenandoah Biotechnology
    • Thermo Fisher Scientific 完成对 Peprotech 的收购，进军重组蛋白领域

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-501246437434

[187 Pages Report] The Recombinant Proteins Market size was estimated at USD 5.05 billion in 2023 and expected to reach USD 5.80 billion in 2024, at a CAGR 14.51% to reach USD 13.04 billion by 2030.

The recombinant proteins are created by inserting a modified gene into an expression system such as bacteria, yeast, or mammalian cells, which then produce the desired protein with high purity and functionality. Recombinant proteins involve research, development, manufacturing, and commercialization of genetically engineered proteins derived from recombinant DNA technology. The prevalence of infectious and chronic diseases, increasing healthcare expenditure needed for new therapeutics and diagnostics, and increased R&D investments within biopharmaceutical companies are raising the need for high-quality recombinant proteins. The rapid advancements in genomics technologies and growing adoption of biologics over small-molecule drugs are resulting in increased adoption of recombinant proteins. However, the high cost of production and maintenance may adversely impact the use of recombinant DNA by the end-use industries. In addition, the emerging applications in animal reproduction and to enhance feed efficiency and significant investments in recombinant protein development are the factors expected to encourage the use of these proteins by the end-use sectors worldwide.

KEY MARKET STATISTICS
Base Year [2023] USD 5.05 billion
Estimated Year [2024] USD 5.80 billion
Forecast Year [2030] USD 13.04 billion
CAGR (%) 14.51%

Product: Significant use of adhesion molecules & receptors for research purposes

Adhesion molecules and receptors are essential for cell-cell communication, migration, and immune response regulation. They are widely used in research to understand cancer, inflammation, and infection. Growth factors and chemokines regulate cellular growth, differentiation, and migration processes. They are vital for wound healing, tissue repair, and stem cell research applications. Immune response proteins are crucial components of the immune system that regulate infection defense mechanisms and inflammation control. Researchers use the immune response proteins to study autoimmune diseases and vaccine development. Kinase proteins are essential in cellular signal transduction pathways regulating cell division, survival, metabolism, and other biological processes. Kinase proteins possess significant potential as drug targets for cancer treatment and management of chronic inflammatory conditions. Membrane proteins are crucial for cell signaling, transport, and adhesion and have applications in drug discovery and development due to their involvement in numerous physiological processes. Recombinant metabolic enzymes are vital in biological pathways regulating cellular metabolism and energy production. They are used in drug discovery efforts targeting metabolic diseases, such as diabetes or obesity. Regulatory proteins control gene expression or cellular processes such as apoptosis and cell cycle progression. They are extensively used for cancer treatment and other diseases involving uncontrolled cell growth or differentiation. Structural proteins provide mechanical support to cells and tissues while maintaining structural integrity within organisms. They find applications in biomedical research related to tissue engineering or regenerative medicine.

Services: Expression services focus on high yields and compatibility with target protein characteristics

Recombinant protein cloning involves the insertion of a target gene into an appropriate expression vector, resulting in a recombinant DNA molecule that directs protein production in host cells. Need-based preferences for cloning services include high efficiency, specificity, and adaptability to different organisms. Expression refers to the process of translating a gene's information into a functional protein product. Several factors influence the choice of an expression system, such as productivity levels, compatibility with post-translational modifications (PTMs), and ease of scale-up for higher yields or purity levels required for downstream applications. Purification is essential to remove contaminants from the expressed protein and prepare it for downstream applications such as drug discovery, diagnostics, and research. Preferences for purification services include high selectivity, reproducibility, yield, and minimal sample loss. The demand for cloning services has increased due to advancements in molecular biology techniques, enabling the generation of multiple clones simultaneously. Expression services have evolved with improvements in host systems to accommodate diverse proteins with varying complexity levels. Purification services continue progressing with resin chemistry and instrumentation advances, allowing higher throughput and yields.

End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies

Academic research institutes are the foundation for innovative and advanced research in recombinant protein technology. These institutes require high-quality, reliable, cost-effective recombinant proteins to study structural biology, functional studies, drug discovery, and diagnostics. Contract manufacturing organizations (CMOs) and contract research organizations (CROs) provide outsourced research and product development services to biopharmaceutical companies specializing in recombinant protein production, assay development, and preclinical testing. They value rapid turnaround times, competitive pricing structures, and customizable offerings tailored to their customer needs. Pharmaceutical biopharmaceutical companies require high-quality, GMP-compliant recombinant proteins for therapeutic and diagnostic product development. These end-user segments prioritize quality, reliability, and cost-effective solutions. Academic research institutes emphasize discovery-driven research application support; biotechnology companies value customization and scalability; CROs and CMOs prioritize turnaround time and customized offerings catering to diverse customers, while pharmaceutical and biopharmaceutical companies require robust manufacturing capabilities with strict regulatory compliance.

Function: Potential demand of recombinant proteins for drug discovery & development

Recombinant proteins are essential in diagnostics, facilitating detection and monitoring of various diseases. Enzyme-linked immunosorbent assays (ELISAs) and lateral flow immunoassays are common diagnostic techniques that utilize recombinant proteins as antigens or antibodies to detect specific biomarkers associated with specific diseases. Recombinant proteins play an indispensable role in drug discovery and production of biologics, vaccines, and cell and gene therapies and serve as potential therapeutic targets or drug candidates themselves. Additionally, they facilitate high throughput screening assays to identify lead compounds targeting specific disease pathways. Diagnostic applications primarily focus on sensitivity, specificity, rapidness, and cost-effectiveness. In contrast, drug discovery & development emphasizes recombinant proteins' purity, stability, scalability, and functional activity.

Regional Insights

The recombinant protein market is evolving in the Americas owing to the presence of well-established pharmaceutical and biotech companies with advanced research facilities and regulations that ensure high-quality products. Additionally, technological advancements, significant increases in funding for research and development (R&D), the rising prevalence of chronic conditions, and a surge in demand for personalized medicines are resulting in an increased need for recombinant protein in the Americas. The EMEA region represents a developing landscape for the recombinant proteins market owing to the stringent regulations implemented to use these proteins and the requirement for manufacturers to adhere to GMP standards. The recombinant proteins market is growing in the APAC region due to the prevalence of chronic diseases, increased research activities in cell biology, biochemistry, structural and biophysical studies, and the need for efficient biopharmaceuticals. Moreover, technological advancements and collaborations between biopharmaceutical companies and academic institutions are expected to increase the translation of laboratory innovations into commercially viable products and boost the adoption of recombinant proteins by the end-use sectors across the globe.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Recombinant Proteins Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Recombinant Proteins Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bhat Bio-tech India Private Limited, Bio-Rad Laboratories, Inc., Biogen Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corp, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., Fortis Life Sciences LLC, GenScript Biotech Corporation, GeoVax Labs, Inc., Hzymes Biotech, Johnson & Johnson Services, Inc., Laurus Labs Limited, LenioBio GmbH, Lonza Group AG, Marin Biologic Laboratories, Inc., Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., Proteintech Group, Inc., Proteos, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Sanofi S.A., Sartorius AG, Selvita S.A., Sino Biological, Inc., SK bioscience, Takara Bio Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins
  • Services
    • Cloning
    • Expression
    • Purification
  • End-User
    • Academic Research Institutes
    • Contract Research Organizations & Contract Manufacturing Organizations
    • Pharmaceutical & Biopharmaceutical Companies
  • Function
    • Diagnostics
    • Drug Discovery & Development
      • Biologics
      • Cell & Gene Therapy
      • Vaccines
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Recombinant Proteins Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Recombinant Proteins Market?

3. What are the technology trends and regulatory frameworks in the Recombinant Proteins Market?

4. What is the market share of the leading vendors in the Recombinant Proteins Market?

5. Which modes and strategic moves are suitable for entering the Recombinant Proteins Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
      • 5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
      • 5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
      • 5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative products and several issues in production
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significant use of adhesion molecules & receptors for research purposes
    • 5.2.2. Services: Expression services focus on high yields and compatibility with target protein characteristics
    • 5.2.3. End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
    • 5.2.4. Function: Potential demand of recombinant proteins for drug discovery & development
  • 5.3. Market Trend Analysis
    • 5.3.1. Increase in research spending coupled with healthcare infrastructure across Americas
    • 5.3.2. Prevalence of chronic diseases and significant investments in medical research in the APAC region
    • 5.3.3. Expanding drug manufacturing facilities and regulatory guidelines for recombinant protein in the EMEA region.
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Recombinant Proteins Market, by Product

  • 6.1. Introduction
  • 6.2. Adhesion Molecules & Receptors
  • 6.3. Growth Factors & Chemokines
  • 6.4. Immune Response Proteins
  • 6.5. Kinase Proteins
  • 6.6. Membrane Proteins
  • 6.7. Recombinant Metabolic Enzymes
  • 6.8. Regulatory Proteins
  • 6.9. Structural Proteins

7. Recombinant Proteins Market, by Services

  • 7.1. Introduction
  • 7.2. Cloning
  • 7.3. Expression
  • 7.4. Purification

8. Recombinant Proteins Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic Research Institutes
  • 8.3. Contract Research Organizations & Contract Manufacturing Organizations
  • 8.4. Pharmaceutical & Biopharmaceutical Companies

9. Recombinant Proteins Market, by Function

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development

10. Americas Recombinant Proteins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Recombinant Proteins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Proteins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
    • 13.3.2. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
    • 13.3.3. Fortis Life Sciences acquires International Point of Care
    • 13.3.4. Curia Expands Cell Line Development Offering with CHOZN Platform
    • 13.3.5. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
    • 13.3.6. Merck's Biodevelopment Centre Expansion, Martillac, France
    • 13.3.7. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
    • 13.3.8. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
    • 13.3.9. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. RECOMBINANT PROTEINS MARKET RESEARCH PROCESS
  • FIGURE 2. RECOMBINANT PROTEINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RECOMBINANT PROTEINS MARKET DYNAMICS
  • FIGURE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RECOMBINANT PROTEINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 334. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 336. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 340. NETHERLANDS RECOMBINANT PROTEINS M